GLOBEALERT
Sign in
The wire

Feed

Open sources, classified and cross-checked. 26,065+ stories.

AllConflictMilitaryPoliticsBusinessSci & TechCyberDisasterHealthWorld
24h3 days7 days30 daysAll·All regionsNorth AmericaSouth AmericaWestern EuropeEastern EuropeBalticsMiddle EastNorth AfricaSub-Saharan AfricaSouth AsiaEast AsiaOceania
DisasterOct 30Survivors of Spain’s worst train crashes urge action after latest disasterAs people suffering post-traumatic stress watch history repeat itself, experts call for investment in safety.Al Jazeera [en]
BusinessOct 30France's economy shrinks 0.1% in Q3 as exports declineFrance's economy saw a 0.1% contraction in the third quarter of the year. This decline is attributed to a decrease in exports.Seeking Alpha Tech
ConflictOct 30Russian strikes on Kyiv kill one, injure another, damage homes and businessesUkrinform [en]
BusinessOct 30Digital Realty targets $8.30-$8.35 2026 core FFO per share as $2.5B backlog lifts confidence into 2027Digital Realty is targeting $8.30-$8.35 for its 2026 core FFO per share. A $2.5 billion backlog is contributing to increased confidence for the company's outlook into 2027.Seeking Alpha Tech
PoliticsOct 30Who pays for a $1 bil riot? Europe looks past rioters to their parents and the apps in their pocketsIn France, the bill for a riot could soon be paid from a family’s housing aid. Some people in a violent crowd could be made to pay for…Japan Today
WorldOct 30Okawara Kako Corporation wrongful conviction, why did the judge deny bail? 'Fear of evidence destruction'A judge denied bail in a wrongful conviction case, citing the risk of evidence destruction. This raises questions about judicial decisions and the justice system.Asahi Shimbun
HealthOct 30Junshi Biosciences Announces the Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS207 in Combination withJS007 for the First-Line Treatment of Advanced Hepatocellular Carcinoma SHANGHAI, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the first patient dosing has been completed in a multi-center, randomized, controlled, and open-label phase 3 clinical study evaluating the efficacy and safety of the company's product, recombinant humanized anti-PD-1/VEGF bispecific antibody (code: JS207), in combination with recombinant humanized anti-CTLA-4 monoclonal antibody (code: JS007) compared to toripalimab in combination with bevacizumab for the first-line treatment of advanced hepatocellular carcinoma (JS207-017-III-HCC Study, NCT07823348). Liver cancer is a common malignant tumor of the digestive system worldwide, with hepatocellular carcinoma (HCC) being the main pathological type (accounting for approximately 90%). China bears an exceptionally heavy disease burden of liver cancer. According to statistics of GLOBOCAN 2024, there were approximately 354,100 new liver cancer cases and 303,800 liver cancer deaths in China in 2024, making it the second leading cause of cancer-related death after lung cancer. Due to its insidious onset, over 50% of patients are diagnosed at an intermediate or advanced stage. Systemic therapy is an important treatment modality for intermediate and advanced liver cancer, which primarily includes molecular targeted drugs, immunotherapy and systemic chemotherapy. However, as the median overall survival of current first-line systemic therapies is less than 2 years, there remain substantial unmet clinical needs for patients with intermediate and advanced liver cancer. In October 2026, the results of a phase 2 clinical study of JS207 in combination with JS007 for the first-line treatment of advanced HCC were presented at the European Society for Medical Oncology (ESMO) Congress 2026 (Abstract No.: #1693eP). The study results showed that the drug combination therapy exhibited robust anti-tumor activity. A total of 36 patients received treatment of JS207 in combination with JS007 (3 mg/kg Q6W for two cycles, and 1 mg/kg Q6W (i.e. recommended dose) thereafter). Among 34 efficacy-evaluable patients, the objective response rate (ORR) of combined treatment reached 44.1%, the disease control rate (DCR) reached 85.3%, the median progression-free survival (PFS) had not yet been reached, and the six-month PFS rate reached 67%. The drug combination therapy was well tolerated. JS207-017-III-HCC study is a multi-center, randomized, controlled, open-label phase 3 clinical study. The study aims to evaluate the efficacy and safety of JS207 in combination with JS007 compared to toripalimab in combination with bevacizumab for the first-line treatment of advanced hepatocellular carcinoma. This study plans to enroll 560 subjects, and the primary endpoints are PFS and overall survival (OS). About JS207 JS207 is a recombinant humanized anti-PD-1/VEGF bispecific antibody self-developed by Junshi Biosciences, mainly used for the treatment of advanced malignant tumors. JS207 can simultaneously bind to PD-1 and VEGFA with high affinity, effectively block the binding of PD-1 to PD-L1 and PD-L2, and inhibit the binding of VEGF to its receptor. JS207 has the efficacy properties of both immunotherapeutic drugs and anti-angiogenic drugs. Through the neutralization of VEGF, JS207 inhibits the proliferation of vascular endothelial cells, improves the tumor microenvironment and increases the infiltration of cytotoxic T lymphocytes in the tumor microenvironment, thereby achieving better anti-tumor activity. JS207 is designed based on the high-affinity, clinically proven and differentiated anti-PD-1 drug toripalimab as the backbone. The anti-PD-1 moiety of JS207 adopts a Fab structure to maintain binding affinity to PD-1 and thereby attain better enrichment in the tumor microenvironment. The anti-VEGF moiety has a binding affinity for human vascular endothelial growth factor that is comparable to that of bevacizumab. In non-clinical in vitro cytological tests, compared with the combination of an anti-PD-1/PD-L1 monoclonal antibody and a VEGF monoclonal antibody, a bispecific antibody simultaneously targeting PD-1/PD-L1 and VEGF demonstrated significantly enhanced PD-1 antigen binding and internalization, and synergistic enhancement of the NFAT signaling pathway, thereby better activating immune cells in the tumor microenvironment. About JS007 JS007 is a recombinant humanized anti-CTLA-4 monoclonal antibody injection self-developed by the Company, mainly used for the treatment of advanced malignant tumors. Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) is an important receptor for T cell surface modulates immune response. Studies have shown that JS007 is able to bind to CTLA-4 specifically and block the interaction between CTLA-4 and its ligand B7 (CD80 or CD86) effectively, thereby activates T-lymphocyte and inhibits the growth of tumor. About Junshi Biosciences Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. With our outstanding capacity for innovative drug discovery, strong biotechnology R&D capability, and large-scale production capacity, we have successfully developed a drug candidate portfolio with global competitiveness and a well-structured research pipeline, which covers therapeutic areas including cancer, autoimmune, metabolic, and infectious diseases. Our innovative field spans cutting-edge therapeutic modalities, including mAbs, small-molecule drugs, ADCs, bsAb/msAb, fusion proteins, nucleic acid drugs and vaccines. Five of the company's products have received marketing authorizations in China and international markets, one of which is toripalimab, China's domestically developed anti-PD-1 monoclonal antibody. Toripalimab has been approved in over 50 countries and regions including China, the US, and Europe. With a mission of "providing patients with world-class, trustworthy, affordable, and innovative drugs," Junshi Biosciences is "In China, For Global." The company currently employs more than 3,000 people worldwide. Headquartered in Shanghai, China, it has a business presence in multiple countries and regions around the world. For more information, please visit: http://www.junshipharma.com. Copyright 2026 GlobeNewswire, Inc.riauone · indonesia
DisasterOct 30Wildfire smoke killed estimated 3,560 people in Indonesia in September: StudyJAKARTA: Smoke from months of wildfires across Indonesia caused an estimated 3,560 deaths in September, twice the August estimate, according to a new study by a Helsinki-based thin...kuwaittimes · kuwait
DisasterOct 30Fire pollution killed 3,560 people in Indonesia in September, report saysThe same month, about 57.8 million people in Indonesia were inhaling unhealthy to hazardous air, according to a new study.japantimes · japan
PoliticsOct 30Bimby Aquino opens up on marriage plans, possible political futureBimby Aquino is already thinking about marriage and a possible future in public service, sharing his personal and political ambitions in "Fast Talk With Boy Abunda." The young celebrity hopes to marry in his mid-to-late twenties and wants his mother, Kris Aquino, and godfather Boy Abunda, whom he calls Ninong, to walk him down the aisle. “I want to marry early. Mid to late 20s, but I'm preferring mid,” he shared. Kris, however, acknowledged the uncertainty surrounding her health when Bimby expressed his wedding wish. “I might not be around. We're being realistic,” she said. Although Bimby has yet to have an official girlfriend, he revealed that Kris has previously encouraged him to date some of his female friends. None of those friendships, however, developed into romance. He also made clear that his future wife must accept his older brother, Josh, who is on the autism spectrum. Recalling Kris' reminder that he would have to look after Josh when she is gone, Bimby said: “If my wife doesn't accept my brother (Josh), no na. I really can't handle that. I can't live without him.” Beyond marriage, Bimby admitted that public service is also on his mind, following a family legacy that includes his grandmother, former President Corazon Aquino, uncles former President Benigno Aquino III and Senator Bam Aquino and grandfather, the late senator Benigno “Ninoy” Aquino Jr. “I have to be honest, a big part of my heart is really leaning towards public service,” he said, acknowledging that Kris taught their family that entering politics involves considerable sacrifice. Bimby said he prefers to begin at the local level, following his grandfather's example. “I prefer to start local. Iba talaga ang boots on the ground,” he explained. Asked whether he could see himself becoming president someday, he confidently replied: “Absolutely.” Despite these ambitions, Bimby said what he admires most about Kris is how she raised him and Josh, rather than her professional accomplishments. “It's the only life I've ever known eh and it's a life that I'd like to think is a very blessed life because I got to come out of the person that I love most,” he said. “No matter what she accomplished, no matter what she did during her professional career, the thing that I admire the most about her is that she raised me right and raised my brother right,” he added. For now, marriage and politics remain plans for the future. But Bimby's love life has already become a topic of public interest, particularly following his recent on-air matchmaking moments with fellow young entertainer Ryzza Mae Dizon. While the pair's interactions have drawn attention, Bimby has yet to confirm any romantic involvement.mb · philippines
PoliticsOct 30Three candidates put forward for Azerbaijan's OmbudsmanThree candidates have been nominated for the position of Azerbaijan's Human Rights Commissioner (Ombudsman), including incumbent Ombudsman Sabina Aliyeva.azernews · azerbaijan
WorldOct 30WBSSC Group C and D Result 2026: Check Merit List and Cut-Off MarksThe WBSSC Group C and D Result 2026 is awaited for the 1st SLST Non-Teaching Examination. The commission conducted the Group C examination on March 1 and the Group D examination on March 8. Candidates should check the official website for results, merit lists and cut-off updates.news_kollegeapply · india
BusinessOct 30MSTR Stock Is Down 44% in a Year, but Michael Saylor Says Strategy Doesn’t Need Bitcoin Or Equity to Do the ‘Heavy Lifting’A company's stock has significantly declined over the past year, but its executive asserts that the strategy does not rely on traditional investments for success. This highlights a company's financial performance and strategic outlook.benzinga · united states of america
WorldOct 30Bugatti Boss Chased His Stolen Chiron In A Porsche 911Leaving the keys in a multi-million-euro hypercar was an invitation a thief couldn't resist.motor1 · united kingdom
PoliticsOct 30It’s Macacua: BARMM Parliament picks region’s first elected chief ministerMacacua's election marks the transition from an appointed interim authority to a regular regional government following parliametary elections on September 14rappler · philippines
BusinessOct 30Vita Resources Advances New Zealand Expansion with Otago Gold HoA and 68km² Bendigo Exploration Permit - Kalkine MediaVita Resources is expanding its operations in New Zealand by securing a gold exploration permit and a Heads of Agreement in the Otago region.kalkinemedia · australia
DisasterOct 30Yellow alert for storms for AMBA and other areas of the provinces of Buenos Aires, Santa Fe, and Entre RíosEl Servicio Meteorológico Nacional lanzó una advertencia por lluvias localmente fuertes para este viernes y anticipó que puede caer granizo en esa región. En qué momentos de la jornada se espera la mayor intensidad.Clarín
PoliticsOct 30French presidential hopeful Édouard Philippe quizzed in embezzlement caseFrench investigators on Thursday questioned former prime minister Édouard Philippe, a candidate in next year's presidential election, in a case of alleged embezzlement of public funds. His lawyer welcomed the move, noting that magistrates had chosen not to place the ex-PM under formal investigation.France 24 [en]
PoliticsOct 30US midterms: 4 days to go – What the polls say as Trump cancels two ralliesTrump cancels Kansas and Iowa rallies, opting for telephone events across nearly 20 states over the weekend.Al Jazeera [en]
BusinessOct 30Amazon Prime Video set to earn ‘tens of billions,’ CEO saysThe CEO of Amazon stated that Amazon Prime Video is expected to earn 'tens of billions.' This indicates significant financial projections for the streaming service.Seeking Alpha Tech
DisasterOct 30Indonesia’s wildfire smoke crisis claims over 3,500 lives in SeptemberSouth China Morning Post
PoliticsOct 30Former Osaka District Public Prosecutors Office chief prosecutor to be released on bail soon; high court rejects public prosecutor's office appealA former Osaka District Public Prosecutors Office chief prosecutor is expected to be released on bail, after a high court rejected an appeal from the public prosecutor's office.Asahi Shimbun
Sci & TechOct 30How China uses gut microbes to treat a range of diseasesModern medicine has spent the past few decades rediscovering the connection between a healthy gut and a healthy mind and body, something traditional Chinese medicine (TCM) practitioners have understood for many hundreds of years. In China and around the world, doctors and scientists trained in Western medicine have learned the importance of maintaining a balance between “good” and “bad” bacteria in the human microbiome – the scientific name for the collection of microorganisms in the gut – and...South China Morning Post
WorldOct 30Student reportedly stabbed with a knife at Tokyo Metropolitan Roppongi High School; classmate arrested on the spotA student was reportedly stabbed with a knife at Tokyo Metropolitan Roppongi High School, leading to the arrest of a classmate on the scene.Asahi Shimbun
← NewerOlder →